Company Overview

Developing and commercialising a range of cell therapies in oncology.

Directors and Management

Ms Leslie (Mi Ok) Chong

Non-Executive Director 28/08/2020

Ms Chong has more than 21 years of oncology experience with clinical development experience in global Phase I-III studies from start-up to registration. Ex Senior Clinical Program Lead at Genentech, one of the biotech businesses developing therapies across all cancer indications. Previously, he was worked at GlaxoSmithKline (NYSE: GSK) and Exelixis (NASDAQ: NEXEL) in cancer therapy development. He has Development experience in oncology with small molecules, immunotherapies, cancer vaccines, oncolytic viral therapies, epigenetics, monoclonal antibodies et al. Ms Chong has experience in clinical development of brain cancer therapies. Ms Chong is currently Chief Executive Officer and Managing Director of Imugene Limited (ASX:IMU); and Non-Executive Director of Cure Brain Cancer Foundation. She is also Chair of the risk management committee of CHM.

Female

Mr Paul Alex Hopper

Founder,Executive Chairman,Executive Director 02/02/2020

Mr Hopper has over 25 years experience in the medical, healthcare & life sciences sectors. His experience covers fund raising in Australia, Asia, US and Europe, and he has experience in corporate governance, risk and strategy. Focussed on start-up and growth companies, he has served as either Founder, Chairman, non-executive director, or Chief Executive Officer, of more than fourteen companies in the US, Australia and Asia. Previous and current Boards include Viralytics (ASX: VLA), Imugene (ASX: IMU), pSivida (ASX: PSD), Polynoma (wholly owned subsidiary of HKG:0775), Somnomed (ASX: SOM), Suda (ASX: SUD), C19 Therapeutics Pty Ltd, and Prescient Therapeutics (ASX: PTX).

BA, ASIA, FAICD Male

Dr Lesley Russell

Non-Executive Director 28/08/2020

Dr Russell has more than 25 years of senior international operational and leadership experience having worked at Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), Cephalon (NASDAQ: CEPH) and Teva (NYSE: TEVA). As Chief Medical Officer and Chief Operating Officer Dr Russell has experience in the therapeutic areas of hematology, oncology, neurology, psychiatry, pain and inflammation, respiratory medicine and stem cell therapy. Dr Russell has knowledge and experience with new drug development along with CART therapies. Dr Russell is currently a Non-Executive Director of Enanta Pharmaceuticals (NASDAQ: ENTA) and Imugene Ltd (ASX:IMU). He is also member of the risk management committee of CHM.

Female

Ms Cynthia Elkins

Non-Executive Director 01/02/2021

--

Female

Dr George Matcham

Non-Executive Director 05/07/2021

Dr Matcham has experience in the biopharma sector, following worked for three decades with cell therapy giant Celgene Corporation. He joined Celgene in its infancy in 1988 when the company was a 30-person startup, retiring in 2018. At Celgene, Dr Matcham championed the introduction of cellular immunotherapy and led the establishment of cell therapy and biologics technical development. At Celgene, Dr Matcham held several senior positions, including Chief Operations Officer of Celgene Cellular Therapeutics and Senior Vice President of CAR T CMC Development, where he oversaw clinical supply. In recent years, Dr Matcham has also served on the board and as an advisor at Instil Bio throughout its financing rounds and IPO.

PhD(Biochemistry),MA, Male

Ms Jennifer Chow

Chief Executive Officer,Managing Director 30/08/2021

Ms Chow has more than 20 years of commercial strategy and marketing experience focused on cellular therapy, hematology and oncology. Prior to joining Chimeric, Ms Chow was Head of Global Marketing, Analytics and Commercial Operations at global CAR T company Kite Pharmaceuticals (acquired by Gilead Sciences in 2017). She was previously Global Cell Therapy Commercial Lead at Celgene Corporation and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche, Nycomed/Takeda and Schering Canada.

Female

Top 20 Shareholders

Director Transactions